Q-omics provides the consensus-scored SEC24D profile across patient tissues and cancer cell-line models. SEC24D expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SEC24D is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, SEC24D protein abundance shows 28,669 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where SEC24D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC24D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC24D survival associations across molecular data types. SEC24D RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC24D RNA expression–survival associations across cancer types. High SEC24D expression shows unfavorable associations in UVM, KIRP, MESO, LGG and STAD, but favorable associations in COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SEC24D RNA expression.
This table summarizes SEC24D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SEC24D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC24D shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, LUAD, COAD and BRCA. The KIRC box plot shows higher SEC24D RNA expression in tumor versus normal tissue (log2 FC = +1.239, t-test p < 0.001).
This table shows molecular features associated with SEC24D in patient tissues and cancer cell lines. In patient samples, SEC24D shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC24D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
